These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 29088719)
1. The downregulation of putative anticancer target BORIS/CTCFL in an addicted myeloid cancer cell line modulates the expression of multiple protein coding and ncRNA genes. Teplyakov E; Wu Q; Liu J; Pugacheva EM; Loukinov D; Boukaba A; Lobanenkov V; Strunnikov A Oncotarget; 2017 Sep; 8(43):73448-73468. PubMed ID: 29088719 [TBL] [Abstract][Full Text] [Related]
2. The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements. Pugacheva EM; Teplyakov E; Wu Q; Li J; Chen C; Meng C; Liu J; Robinson S; Loukinov D; Boukaba A; Hutchins AP; Lobanenkov V; Strunnikov A Epigenetics Chromatin; 2016; 9(1):35. PubMed ID: 27588042 [TBL] [Abstract][Full Text] [Related]
3. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943 [TBL] [Abstract][Full Text] [Related]
4. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009 [TBL] [Abstract][Full Text] [Related]
5. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944 [TBL] [Abstract][Full Text] [Related]
6. Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions. Pugacheva EM; Rivero-Hinojosa S; Espinoza CA; Méndez-Catalá CF; Kang S; Suzuki T; Kosaka-Suzuki N; Robinson S; Nagarajan V; Ye Z; Boukaba A; Rasko JE; Strunnikov AV; Loukinov D; Ren B; Lobanenkov VV Genome Biol; 2015 Aug; 16(1):161. PubMed ID: 26268681 [TBL] [Abstract][Full Text] [Related]
7. The structural complexity of the human BORIS gene in gametogenesis and cancer. Pugacheva EM; Suzuki T; Pack SD; Kosaka-Suzuki N; Yoon J; Vostrov AA; Barsov E; Strunnikov AV; Morse HC; Loukinov D; Lobanenkov V PLoS One; 2010 Nov; 5(11):e13872. PubMed ID: 21079786 [TBL] [Abstract][Full Text] [Related]
8. Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells. Rivero-Hinojosa S; Kang S; Lobanenkov VV; Zentner GE Sci Rep; 2017 Feb; 7():41279. PubMed ID: 28145452 [TBL] [Abstract][Full Text] [Related]
9. BORIS/CTCFL-mediated chromatin accessibility alterations promote a pro-invasive transcriptional signature in melanoma cells. Moscona R; Janssen SM; Elchebly M; Papadakis AI; Rubin E; Spatz A Pigment Cell Melanoma Res; 2023; 36(3-4):299-313. PubMed ID: 37082838 [TBL] [Abstract][Full Text] [Related]
10. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. Link PA; Zhang W; Odunsi K; Karpf AR Cancer Immun; 2013; 13():6. PubMed ID: 23390377 [TBL] [Abstract][Full Text] [Related]
12. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells. Alberti L; Losi L; Leyvraz S; Benhattar J PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996 [TBL] [Abstract][Full Text] [Related]
13. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639 [TBL] [Abstract][Full Text] [Related]
14. CTCF and BORIS in genome regulation and cancer. Marshall AD; Bailey CG; Rasko JE Curr Opin Genet Dev; 2014 Feb; 24():8-15. PubMed ID: 24657531 [TBL] [Abstract][Full Text] [Related]
15. Discovering a binary CTCF code with a little help from BORIS. Lobanenkov VV; Zentner GE Nucleus; 2018 Jan; 9(1):33-41. PubMed ID: 29077515 [TBL] [Abstract][Full Text] [Related]
16. The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation. Jelinic P; Stehle JC; Shaw P PLoS Biol; 2006 Oct; 4(11):e355. PubMed ID: 17048991 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Hoffmann MJ; Müller M; Engers R; Schulz WA Biochem Pharmacol; 2006 Nov; 72(11):1577-88. PubMed ID: 16854382 [TBL] [Abstract][Full Text] [Related]
18. The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells. Zampieri M; Ciccarone F; Palermo R; Cialfi S; Passananti C; Chiaretti S; Nocchia D; Talora C; Screpanti I; Caiafa P Biochim Biophys Acta; 2014 Sep; 1839(9):813-25. PubMed ID: 24984200 [TBL] [Abstract][Full Text] [Related]
19. MAGEA1 inhibits the expression of BORIS via increased promoter methylation. Zhao J; Wang Y; Liang Q; Xu Y; Sang J J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011 [TBL] [Abstract][Full Text] [Related]
20. The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer. Salgado-Albarrán M; González-Barrios R; Guerra-Calderas L; Alcaraz N; Estefanía Sánchez-Correa T; Castro-Hernández C; Sánchez-Pérez Y; Aréchaga-Ocampo E; García-Carrancá A; Cantú de León D; Herrera LA; Baumbach J; Soto-Reyes E Oncogenesis; 2019 Aug; 8(8):41. PubMed ID: 31406110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]